Related Experiment Video
Updated: Jul 31, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk
Vijay Nambi1, Christie M Ballantyne
1Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Insights
High-sensitivity C-reactive protein (CRP) shows potential for predicting cardiovascular events, even with low cholesterol. Ongoing studies will determine if targeting high CRP levels with statins improves outcomes.
Area of Science:
- Cardiology
- Biomarkers
- Inflammation
Background:
- High-sensitivity C-reactive protein (CRP) is an emerging biomarker for cardiovascular event risk.
- CRP predicts risk independently of traditional factors and in patients with low LDL cholesterol.
- Statins are known to reduce CRP levels.
Purpose of the Study:
- To evaluate the impact of targeting high CRP in patients with low LDL cholesterol on cardiovascular events and survival.
- To determine if changes in CRP correlate with cardiovascular event reduction.
Main Methods:
- Observational studies and clinical trials are investigating the role of CRP.
- Focus on patient populations with high CRP and low LDL cholesterol.
- Monitoring cardiovascular events, survival rates, and CRP level changes.
Main Results:
- CRP is a significant predictor of cardiovascular events.
- Statins reduce CRP levels, suggesting a potential therapeutic link.
- Ongoing studies are crucial for definitive conclusions.
Conclusions:
- CRP is a valuable prognostic marker for cardiovascular disease.
- The therapeutic utility of CRP as a target requires further investigation.
- Current research aims to clarify the role of CRP-targeted therapies in cardiovascular risk reduction.
Abstract:
High-sensitivity C-reactive protein (CRP), a nonspecific marker of inflammation, is a newly available biomarker for predicting the risk of cardiovascular events. CRP has been shown to predict risk of cardiovascular events independent of traditional risk factors and in the setting of low levels of low-density lipoprotein cholesterol. Statins have been shown to decrease CRP, and studies are now under way to evaluate if targeting patients with high CRP and low low-density lipoprotein cholesterol will have any impact on future cardiovascular events and survival and whether changes in CRP correlate to event reduction. The utility of CRP as a target of therapy remains to be proved, and these ongoing studies will likely provide us with guidance.
More Related Videos
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Coronary Artery Disease IV: Preventive Measures
Acute Coronary Syndrome III: Diagnostic Studies
Atherosclerosis III: Management

